337 F. Supp. 3d 371
D. Del.2018Background
- Galderma (plaintiffs) sued Amneal under the Hatch‑Waxman Act after Amneal filed an ANDA to market a 40 mg once‑daily generic of Oracea (doxycycline). Plaintiffs asserted multiple Chang patents (formulation claims) and Ashley patents (method-of-treatment claims).
- Oracea is a 40 mg doxycycline capsule composed of 30 mg immediate‑release (IR) beads plus 10 mg delayed‑release (DR) beads intended to provide steady‑state blood levels of ~0.1–1.0 µg/ml and treat inflammatory rosacea lesions without antibacterial effects.
- Amneal’s ANDA product is a bioequivalent 40 mg once‑daily doxycycline capsule with different internal bead/coating technology (redacted technical details) and labeling identical to Oracea’s indication for rosacea.
- After a five‑day bench trial, the court found (inter alia) that Amneal infringed several Chang and Ashley II patent claims under the doctrine of equivalents (DOE), but did not infringe the Chang ’532 claim (which requires enteric‑coated pellets) nor the Ashley I asserted claims (those were collaterally estopped).
- The court rejected Amneal’s attacks on Ashley patents for lack of enablement, lack of written description, anticipation, obviousness, and indefiniteness—concluding Amneal failed to prove invalidity by clear and convincing evidence.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Amneal’s ANDA product infringes asserted Chang patent claims (DOE) | Amneal’s combination of internal components functions as a DR portion (delays release) equivalent to Chang’s 10 mg DR bead, so DOE applies | Amneal: components either release immediately or are not equivalent; prosecution estoppel and prior IPR statements bar DOE | Court: found DOE infringement of Chang ’740, ’405, ’364 claims (preponderance) but no infringement of Chang ’532 (requires enteric polymer) |
| Whether prosecution history estoppel or disclaimer prevents DOE for Chang claims | Galderma: amendments and IPR statements do not clearly and unmistakably surrender equivalents | Amneal: narrowed claim language and IPR statements surrendered equivalents | Court: estoppel/disclaimer not shown; DOE preserved for asserted Chang claims (except ’532) |
| Whether Galderma is collaterally estopped from asserting Ashley I patents (sub‑antibacterial limitation) | Galderma: DOE theory is distinct and was not litigated in prior Mylan case | Amneal: identical issue already litigated and decided (40 mg once‑daily fails sub‑antibacterial limitation) | Court: collateral estoppel applies; Galderma precluded from asserting Ashley I claims (literal or DOE) against Amneal |
| Whether Amneal’s ANDA product infringes Ashley II claims and whether those claims are invalid | Galderma: Skidmore (Example 38) and labeling show 40 mg once‑daily results in no reduction of skin microflora over six months; thus DOE infringement and claims enabled/ described | Amneal: Skidmore sampled only one site; literal infringement not proven; claims lack enablement/written description and are anticipated/obvious; indefiniteness of sub‑antibacterial terms | Court: literal infringement not proven, but DOE infringement found for Ashley II asserted claims; Amneal failed to prove invalidity by clear and convincing evidence |
Key Cases Cited
- Markman v. Westview Instruments, Inc., 52 F.3d 967 (Fed. Cir.) (claim construction is a two‑step process) (cited for infringement analysis)
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002) (prosecution history estoppel limits DOE) (doctrine discussed)
- Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950) (framework for evaluating equivalence: function‑way‑result) (DOE analysis)
- Warner‑Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997) (role of claim element context in DOE) (DOE analysis)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (flexible obviousness inquiry; avoid hindsight) (obviousness standard)
- Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (2014) (indefiniteness: claims must inform with reasonable certainty) (indefiniteness standard)
- Research Foundation of State Univ. of N.Y. v. Mylan Pharm., Inc., 809 F. Supp. 2d 296 (D. Del. 2011) (prior non‑infringement finding on 40 mg doxycycline; used here for collateral estoppel)
- Galderma Labs., Inc. v. Amneal Pharm., LLC, 921 F. Supp. 2d 278 (D. Del. 2012) (court previously held collateral estoppel against Galderma re: Ashley I patents) (precedent on estoppel)